Q2 FY2026 · ended Jun 30, 2026 · Revenue $3.75B, +5.0% YoY · Filed Aug 6, 2026
Viatris Inc. (VTRS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $3.7 billion. Free cash flow was $329.0 million. As of Jun 30, 2026 it held $886.5 million in cash and investments and $13.6 billion in total debt.
Revenue
$3.75B
+5.0% vs year-ago quarter
Net income
—
Operating cash flow
$381.80M
+73.8% vs year-ago quarter
Free cash flow
$329.00M
+97.2% vs year-ago quarter
EPS
$-0.10
Dividend per share
$0.12
+0.0% vs year-ago quarter
Shares outstanding
1.15B
-1.5% vs year-ago quarter
Net cash
$-12.74B
Q2 FY2026
Operating margin
-0.6%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VTRS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Canonsburg, PA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1792044
- Former names
- Upjohn Inc (until Nov 10, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $3.7B | $3.5B | $3.7B | $3.7B | $3.6B |
| Operating income | $6.3M | -$79.7M | -$192.7M | $178.8M | $233.0M |
| Diluted EPS | -$0.10 | $0.15 | — | -$0.11 | $0.00 |
| Operating cash flow | $381.8M | $388.3M | $815.8M | $744.9M | $219.7M |
| Free cash flow | $329.0M | $348.4M | $619.3M | $658.1M | $166.8M |
| Total assets | $35.0B | $36.8B | $37.2B | $37.9B | $38.4B |
| Total liabilities | $20.8B | $22.2B | $22.5B | $22.7B | $22.8B |
| Stockholders' equity | $14.3B | $14.7B | $14.7B | $15.2B | $15.6B |
| Cash and investments | $886.5M | $1.8B | $1.4B | $975.3M | $566.4M |
| Total debt | $13.6B | $14.6B | $14.7B | $14.7B | $14.8B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 8, 2026 | Oct 8, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 1, 2026 | Jul 1, 2026 |
All 544 Viatris Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.